Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Gross Margin (2021 - 2025)

InMed Pharmaceuticals has reported Gross Margin over the past 5 years, most recently at 22.46% for Q4 2025.

  • For Q4 2025, Gross Margin fell 1900.0% year-over-year to 22.46%; the TTM value through Dec 2025 reached 29.73%, down 566.0%, while the annual FY2025 figure was 34.53%, 1058.0% up from the prior year.
  • Gross Margin for Q4 2025 was 22.46% at InMed Pharmaceuticals, down from 35.99% in the prior quarter.
  • Over five years, Gross Margin peaked at 67.95% in Q2 2023 and troughed at 153.07% in Q3 2022.
  • A 5-year average of 23.38% and a median of 35.99% in 2025 define the central range for Gross Margin.
  • On a YoY basis, Gross Margin climbed as much as 15542bps in 2023 and fell as far as -4026bps in 2023.
  • Year by year, Gross Margin stood at 42.08% in 2021, then crashed by -34bps to 27.92% in 2022, then decreased by -6bps to 26.14% in 2023, then surged by 59bps to 41.46% in 2024, then crashed by -46bps to 22.46% in 2025.
  • Business Quant data shows Gross Margin for INM at 22.46% in Q4 2025, 35.99% in Q3 2025, and 44.2% in Q2 2025.